Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Two vaccines are now approved for use against Plasmodium falciparum malaria in young African children; these can prevent liver infection. However, if a single parasite slips through the net, blood-stage infection is established causing clinical disease. An effective blood-stage vaccine (or second line of defence), however, has proved elusive. We have developed vaccines targeting the P. falciparum RH5 antigen, which mediates a conserved and essential invasion pathway into the human red blood cell. Rational vaccine design has built on our understanding of how vaccine-induced anti-RH5 human antibodies inhibit parasite growth. This talk will describe our work to understand human anti-malarial antibodies and present data from Phase 1/2 clinical trials of RH5-based blood-stage vaccines undertaken in the UK and across Africa.
